Efficacy of Alkylating Agent Re-challenge after Therapeutic Pause in Metastatic Pancreatic Neuroendocrine Tumors (PanNET)
Introduction: Temozolomide (TMZ) and dacarbazine (DTIC) are alkylating agents (ALK) with antitumor efficacy in metastatic PanNET. Rechallenging ALK following prior efficacy is commonly performed but has not been evaluated.
Aim(s): To evaluate the efficacy and tolerance of ALK rechallenge in advanced PanNET.
Materials and methods: In this retrospective multicentre study (2006-2019), we included consecutive patients with advanced PanNET who were treated by ALK1 (TMZ or DTIC, +/- fluoropyrimidine) with initial efficacy, followed by a pause > 3 months without cytotoxic treatment, then rechallenge at progression (ALK2). Progression-free survival for ALK1 (PFS1) and ALK2 (PFS2) were calculated. Cox regression models explored variables associated with PFS2. We compared tolerance to ALK1 and ALK2 by Mc Nemar test.
Conference: 17th Annual ENETSConcerence (2020)
To read the full abstract, please log into your ENETS Member account.